Insulet Wins $452M Verdict in Patent Battle with EOFlow

A federal jury awarded Insulet Corporation $452 million in damages after finding South Korean competitor EOFlow guilty of misappropriating trade secrets related to Insulet’s Omnipod insulin pumps. The breakdown includes $170 million in compensatory damages and $282 million in exemplary damages for willful misconduct. The case, filed in Massachusetts in 2023, accused EOFlow and three former Insulet executives of copying patented components of the Omnipod system.

This legal victory solidifies Insulet's dominance in the U.S. insulin patch pump market, a space poised for competition with upcoming products from Tandem Diabetes Care and Medtronic. EOFlow faced additional setbacks earlier, including a preliminary injunction (later overturned) and the collapse of a $738 million acquisition deal with Medtronic. Insulet CEO Jim Hollingshead lauded the jury's decision, while EOFlow has yet to comment. The ruling marks a significant precedent in the medtech industry’s patent wars.